Regeneron Pharmaceuticals Inc (REGN) Stock Forecast
US · Healthcare
Current price
$620.14
Market cap
$65.01B
Mean price target
$833.31
Implied upside
34.4%
Key takeaways
- Analysts rate Regeneron Pharmaceuticals Inc a “Buy”, with a mean price target of $833.31 — about 34.4% upside from the current $620.14, based on 28 analysts.
- REGN is trading in the middle of its 52-week range, at 34% of the $514.79–$821.11 band.
Analyst consensus
| Consensus rating | Buy |
|---|---|
| Number of analysts | 28 |
| Mean target | $833.31 |
| High target | $1,000.00 |
| Low target | $641.00 |
| Rating split (SB / B / H / S / SS) | 4 / 18 / 7 / 0 / 0 |
Price & trading
| Current price | $620.14 |
|---|---|
| Previous close | $623.27 |
| 52-week high | $821.11 |
| 52-week low | $514.79 |
| 50-day average | $671.85 |
| Beta | 0.24 |
See the full REGN breakdown on Luminoso
Valuation, profitability, efficiency, leverage & earnings-quality metrics — updated daily.
Start free — 2 months on usFrequently asked questions
- What is the current Regeneron Pharmaceuticals Inc (REGN) share price?
- Regeneron Pharmaceuticals Inc last traded at $620.14 with a market capitalisation of about $65.0B.
- What is the analyst price target for REGN?
- The mean analyst price target for Regeneron Pharmaceuticals Inc is $833.31, roughly 34.4% above the latest price. The current consensus rating is “Buy”.
- Where can I see Regeneron Pharmaceuticals Inc's full financial metrics?
- Luminoso tracks REGN's valuation, profitability, efficiency, leverage and earnings-quality metrics alongside analyst data — updated daily. Create a free account to explore the full breakdown.
More stocks
Browse all companies covered by Luminoso →
Last updated 25 Jun 2026.
Data is provided for informational purposes only and is not investment advice. Figures are cached and refreshed daily; they may differ from real-time quotes.